Investigational Drug Information for INCB054707
✉ Email this page to a colleague
What is the development status for investigational drug INCB054707?
INCB054707 is an investigational drug.
There have been 11 clinical trials for INCB054707.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 14th 2022.
The most common disease conditions in clinical trials are Hidradenitis Suppurativa, Hidradenitis, and Kidney Diseases. The leading clinical trial sponsors are Incyte Corporation, Incyte Biosciences Japan GK, and [disabled in preview].
There are fifteen US patents protecting this investigational drug and two hundred and thirteen international patents.
Summary for INCB054707
| US Patents | 15 |
| International Patents | 213 |
| US Patent Applications | 94 |
| WIPO Patent Applications | 22 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2022-12-14) |
| Vendors | 9 |
Recent Clinical Trials for INCB054707
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | Incyte Corporation | Phase 1 |
| Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis | Incyte Corporation | Phase 1 |
| A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | Incyte Corporation | Phase 3 |
Clinical Trial Summary for INCB054707
Top disease conditions for INCB054707
Top clinical trial sponsors for INCB054707
US Patents for INCB054707
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| INCB054707 | ⤷ Try a Trial | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
| INCB054707 | ⤷ Try a Trial | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
| INCB054707 | ⤷ Try a Trial | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
| INCB054707 | ⤷ Try a Trial | Heterocyclic compounds as PI3K-.gamma. inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
| INCB054707 | ⤷ Try a Trial | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for INCB054707
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| INCB054707 | World Intellectual Property Organization (WIPO) | WO2017027717 | 2035-08-12 | ⤷ Try a Trial |
| INCB054707 | World Intellectual Property Organization (WIPO) | WO2017035366 | 2035-08-26 | ⤷ Try a Trial |
| INCB054707 | Australia | AU2015244044 | 2034-04-08 | ⤷ Try a Trial |
| INCB054707 | Australia | AU2020213313 | 2034-04-08 | ⤷ Try a Trial |
| INCB054707 | Australia | AU2022206693 | 2034-04-08 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
